WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 532075
Description: L-739,750 is a peptidomimetic farnesyltransferase inhibitor (FTI).
MedKoo Cat#: 532075
Chemical Formula: C23H39N3O6S2
Exact Mass: 517.228
Molecular Weight: 517.7
Elemental Analysis: C, 53.36; H, 7.59; N, 8.12; O, 18.54; S, 12.39
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: L-739750; L 739750; L739750.
IUPAC/Chemical Name: (2S)-2-[[(2S)-2-[(2S,3S)-2-[[(2R)-2-amino-3-sulfanylpropyl]amino]-3-methylpentoxy]-3-phenylpropanoyl]amino]-4-methylsulfonylbutanoic acid
InChi Key: SIEXHGZWGJLLAC-OSTWSGHESA-N
InChi Code: InChI=1S/C23H39N3O6S2/c1-4-16(2)20(25-13-18(24)15-33)14-32-21(12-17-8-6-5-7-9-17)22(27)26-19(23(28)29)10-11-34(3,30)31/h5-9,16,18-21,25,33H,4,10-15,24H2,1-3H3,(H,26,27)(H,28,29)/t16-,18+,19-,20+,21-/m0/s1
SMILES Code: O=C(O)[C@@H](NC([C@@H](OC[C@@H](NC[C@@H](N)CS)[C@@H](C)CC)CC1=CC=CC=C1)=O)CCS(=O)(C)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 517.7 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Assem N, Yudin AK. Convergent synthesis of aminomethylene peptidomimetics. Nat Protoc. 2012 Jun 14;7(7):1327-34. doi: 10.1038/nprot.2012.066. PubMed PMID: 22722368.
2: Long SB, Hancock PJ, Kral AM, Hellinga HW, Beese LS. The crystal structure of human protein farnesyltransferase reveals the basis for inhibition by CaaX tetrapeptides and their mimetics. Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):12948-53. PubMed PMID: 11687658; PubMed Central PMCID: PMC60805.
3: Koblan KS, Culberson JC, Desolms SJ, Giuliani EA, Mosser SD, Omer CA, Pitzenberger SM, Bogusky MJ. NMR studies of novel inhibitors bound to farnesyl-protein transferase. Protein Sci. 1995 Apr;4(4):681-8. PubMed PMID: 7613466; PubMed Central PMCID: PMC2143100.
4: Kohl NE, Wilson FR, Mosser SD, Giuliani E, deSolms SJ, Conner MW, Anthony NJ, Holtz WJ, Gomez RP, Lee TJ, et al. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):9141-5. PubMed PMID: 8090782; PubMed Central PMCID: PMC44763.